Genelux Corporation

NASDAQ:GNLX

Biotechnology

Healthcare
$2.24 +2.63%

+$0.08 today

Market cap
$107.66M
Beta
0.55
P/E (TTM)
-3.0
EPS (TTM)
-$0.98
52W Low $2.29High $8.54

Volume 0.80M

Average 0.19M

GNLX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Genelux CorporationNASDAQ: GNLX

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $1K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $292K. Over 3 fiscal years it compounded at -16.0% a year.

Context

  • Cost of revenue amounted to 7175.0% of revenue in FY2025, down 4112.5 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $1K or moves back toward the trailing-twelve-month quarterly average of $73K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1K-99.3% QoQ
Last fiscal yearDec 2025
$574K-36.4% YoY
LTMMar 2026
$292K+43.1% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-36.4%——
3-year CAGR-16.0%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
574K USD
Year-over-year change
-36.4%
4-year CAGR
-10.5%

Cost of Revenue vs competitors

How GNLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +43.1% is the highest of 3, against a peer median of +17.1%.
  • Cost of revenue amounts to 3650.0% of revenue for GNLX, versus a peer median of 33.6%.
GNLX Competitors
Cost of Revenue for GNLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$12.33M USD+39.3%+4.9%18.1%
LYELLyell Immunopharma, Inc.LTM Mar 2026$2.33M USD——7522.6%
MREOMereo BioPharma Group plcLTM Mar 2026$1.03M USD-5.2%—205.7%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$546K USD———
SLNSilence Therapeutics plcLTM Mar 2026$309.37K USD—-73.0%33.6%
GNLXGenelux CorporationLTM Mar 2026$292K USD+43.1%-16.0%3650.0%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$79K USD———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$66.6K USD———
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$0 USD—+8.0%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$0 USD———
ACIUAC Immune S.A.LTM Mar 2026CHF 0 CHF——0.0%
Peer median (excluding GNLX) —+17.1%+4.9%33.6%

Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue011.07M170K8K8K
Cost of Revenue895K968K1.02M903K574K
Gross Profit(895K)10.1M(848K)(895K)(566K)
Gross Margin—91.3%-498.8%-11187.5%-7075.0%
Research & Development6.32M9.08M12.77M19M19.85M
Selling, General & Admin8.29M5M11.57M12.71M13.37M
Operating Expenses13.72M13.11M23.32M30.8M32.65M
Depreciation & Amortization895K968K1.02M903K574K
EBITDA(13.67M)(1.73M)(26.46M)(28.97M)(31.57M)
EBITDA Margin—-15.6%-15562.9%-362075.0%-394637.5%
Operating Income(14.61M)(3.01M)(24.17M)(31.7M)(33.21M)
Operating Margin—-27.2%-14214.7%-396200.0%-415175.0%
Interest Income00244K1.46M1.07M
Interest Expense1.82M1.41M3.97M00
Other Income / Expenses(1.77M)(1.09M)(4.13M)1.83M1.07M
Income Before Tax(16.38M)(4.11M)(28.3M)(29.87M)(32.15M)
Pre-Tax Margin—-37.1%-16645.3%-373362.5%-401812.5%
Income Tax Expense01.1M000
Net Income(17.8M)(5.21M)(28.3M)(29.87M)(32.15M)
Net Margin—-47.0%-16645.3%-373362.5%-401812.5%
EPS (Basic)(0.69)(0.21)(1.16)(0.95)(0.86)
EPS (Diluted)(0.69)(0.21)(1.16)(0.95)(0.86)
Weighted Avg Shares23.62M24.55M24.43M31.45M37.18M
Weighted Avg Shares (Diluted)23.62M24.55M24.43M31.45M37.18M

Genelux Corporation

NASDAQ:GNLX

Intrinsic Alpha fair value

Locked

Current Price

$2.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.